Are you over 18 and want to see adult content?
More Annotations
Click Paraná - O Portal de Notícias da sua Cidade!
Are you over 18 and want to see adult content?
Enchères en ligne d'objets d'exception - Catawiki
Are you over 18 and want to see adult content?
Reel Pizza Cinerama - Bar Harbor, Maine, movie theater.
Are you over 18 and want to see adult content?
Globalme | Data Collection & Technology Localization Company
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://theappendix.net
Are you over 18 and want to see adult content?
A complete backup of https://kingshorewindowsanddoors.com
Are you over 18 and want to see adult content?
A complete backup of https://tutorialrepublic.com
Are you over 18 and want to see adult content?
A complete backup of https://britishbeer.com
Are you over 18 and want to see adult content?
A complete backup of https://smallcubed.com
Are you over 18 and want to see adult content?
A complete backup of https://frankfurter-volksbank.de
Are you over 18 and want to see adult content?
A complete backup of https://mandmmachinery.com
Are you over 18 and want to see adult content?
A complete backup of https://yourworkbookforsuccess.com
Are you over 18 and want to see adult content?
A complete backup of https://n4gm.com
Are you over 18 and want to see adult content?
A complete backup of https://kompiwin.com
Are you over 18 and want to see adult content?
A complete backup of https://hopva.org
Are you over 18 and want to see adult content?
A complete backup of https://campaignme.com
Are you over 18 and want to see adult content?
Text
CONTACT - PERLARA
We’re having an ongoing conversation with families and researchers about collaborations that will lead to cures. Please contact us so that we can share what we learn, and learn from you. Email: info@perla ra.com. Office: 6000 Shoreline Ct. Suite 204. South San Francisco.California 94080.
PERLARA IS A PUBLIC BENEFIT CORPORATION ACCOUNTABLE FOR Public Benefit Corporation. We chose to incorporate as the first biotech Public Benefit Corporation because we are accountable for our actions as a company and as individuals within the context of a balanced and healthy global economy and environment. PBC report. Since our founding in 2014, our mission has guided our actions—fromoperating
PERLARK™ DRUG DISCOVERY PLATFORM USED TO IDENTIFY ORPHAN Perlara uses a platform of genetically engineered animals (yeast, nematodes, fruit flies and zebrafish) in phenotypic screens to identify orphan drug candidates that reverse disease much faster and cheaper than current approaches. PERLARA ANNOUNCES APOL1 KIDNEY DISEASE PERLQUEST Perlara, the rare diseases platform company that partners with highly motivated families, organizations, researchers and impact investors to cure rare genetic diseases, today announced an APOL1 kidney disease PerlQuest co-development partnership with Rambam Medical Center in Haifa, Israel, and the laboratory of leading nephrologist and kidney CONSERVATION OF FAT STORAGE AND MOBILIZATION IN Conservation of Fat Storage and Mobilization in Drosophila. Lipids are stored in cellular locales called “lipid droplets.”. The lipid droplet surface is a lipid monolayer coated with specific proteins. The best known lipid droplet surface proteins are “PAT” NEIMAN-PICK TYPE C KO MOUSE BRAIN STUDY The presence of CD68 is often used to measure the inflammatory response in the brain and is expressed more highly in many neurodegenerative diseases, including in the brains of Niemann Pick C mice and humans (brown areas of stain in panel (C) and (D) are of CD68). Figure 2. CD68 in the brain of NPC1 patient samples. ETHAN PERLSTEIN IS CHIEF EXECUTIVE OFFICER AT PERLARA. Ethan Perlstein, PhD | CEO. Over the course of the last decade, first as a graduate student at Harvard University in the Department of Molecular and Cell Biology with PhD advisor Professor Stuart Schreiber and then as an independent postdoctoral fellow at the Lewis-Sigler Institute at Princeton University, Dr. Ethan Perlstein developed an approach to studying old drugs and discovering new THE NIEMANN-PICK C/EBOLA CONNECTION Now, based on our previous NPC posts you know that individuals with Niemann-Pick type C disease accumulate cholesterol in the endosome/lysosome compartments. Researchers in this study checked to see if it was the accumulation of cholesterol that affected the lack of viral infectivity. They treated NPC2-/-, NPC2 +/- and wt littermates with EBOV. ACOUSTIC LIQUID HANDLING LABCYTE ECHO 550 FOR HIGH Labcyte Echo 550 acoustic liquid handling for high throughput screening of potential drug candidates. Liquid handling is essential to HTS assays as the drug discovery experiment pipeline includes screening millions of compounds to identify as a potential drug candidate. The A coustic Droplet Ejection (ADE) is a technology whichuses highly
PERLARA PBC IS WORKING WITH FAMILIES TO DEVELOP CURES FORABOUT USOUR SCIENCEPERLQUESTSFAQSBLOGNEWS Perlara scientists are working with highly motivated families, patient organizations and researchers to develop cures for rare diseases and learn how genes work across diseases to map connections to common ailments. We call these exciting journeys of discoveryCONTACT - PERLARA
We’re having an ongoing conversation with families and researchers about collaborations that will lead to cures. Please contact us so that we can share what we learn, and learn from you. Email: info@perla ra.com. Office: 6000 Shoreline Ct. Suite 204. South San Francisco.California 94080.
PERLARA IS A PUBLIC BENEFIT CORPORATION ACCOUNTABLE FOR Public Benefit Corporation. We chose to incorporate as the first biotech Public Benefit Corporation because we are accountable for our actions as a company and as individuals within the context of a balanced and healthy global economy and environment. PBC report. Since our founding in 2014, our mission has guided our actions—fromoperating
PERLARK™ DRUG DISCOVERY PLATFORM USED TO IDENTIFY ORPHAN Perlara uses a platform of genetically engineered animals (yeast, nematodes, fruit flies and zebrafish) in phenotypic screens to identify orphan drug candidates that reverse disease much faster and cheaper than current approaches. PERLARA ANNOUNCES APOL1 KIDNEY DISEASE PERLQUEST Perlara, the rare diseases platform company that partners with highly motivated families, organizations, researchers and impact investors to cure rare genetic diseases, today announced an APOL1 kidney disease PerlQuest co-development partnership with Rambam Medical Center in Haifa, Israel, and the laboratory of leading nephrologist and kidney CONSERVATION OF FAT STORAGE AND MOBILIZATION IN Conservation of Fat Storage and Mobilization in Drosophila. Lipids are stored in cellular locales called “lipid droplets.”. The lipid droplet surface is a lipid monolayer coated with specific proteins. The best known lipid droplet surface proteins are “PAT” NEIMAN-PICK TYPE C KO MOUSE BRAIN STUDY The presence of CD68 is often used to measure the inflammatory response in the brain and is expressed more highly in many neurodegenerative diseases, including in the brains of Niemann Pick C mice and humans (brown areas of stain in panel (C) and (D) are of CD68). Figure 2. CD68 in the brain of NPC1 patient samples. ETHAN PERLSTEIN IS CHIEF EXECUTIVE OFFICER AT PERLARA. Ethan Perlstein, PhD | CEO. Over the course of the last decade, first as a graduate student at Harvard University in the Department of Molecular and Cell Biology with PhD advisor Professor Stuart Schreiber and then as an independent postdoctoral fellow at the Lewis-Sigler Institute at Princeton University, Dr. Ethan Perlstein developed an approach to studying old drugs and discovering new THE NIEMANN-PICK C/EBOLA CONNECTION Now, based on our previous NPC posts you know that individuals with Niemann-Pick type C disease accumulate cholesterol in the endosome/lysosome compartments. Researchers in this study checked to see if it was the accumulation of cholesterol that affected the lack of viral infectivity. They treated NPC2-/-, NPC2 +/- and wt littermates with EBOV. ACOUSTIC LIQUID HANDLING LABCYTE ECHO 550 FOR HIGH Labcyte Echo 550 acoustic liquid handling for high throughput screening of potential drug candidates. Liquid handling is essential to HTS assays as the drug discovery experiment pipeline includes screening millions of compounds to identify as a potential drug candidate. The A coustic Droplet Ejection (ADE) is a technology whichuses highly
GET THE LATEST PERLARA NEWS ABOUT PERLQUESTS, SCIENCE, AND August 15, 2018. Perlara announces Glycogen Storage Diseases PerlQuest with the University of Notre Dame. July 11, 2018. Perlara announces n=1 drug discovery pact with Mission: Cure. April 9, 2018. Perlara announces partnership with Multiple Sulfatase Deficiency Action Foundation. March 2, 2018. Perlara announces collaboration withUndiagnosed
PERLARK DRUG DISCOVERY PLATFORM TO HELP FIND RARE DISEASE 1. Build an Ark. We use gene editing technology to model specific human diseases in simple animals like yeasts, worms, flies and fish. Think Noah’s Ark of Drug Discovery. 2. Try out a boat load of compounds. We screen compounds on our disease models, and gather massive amounts of chemical and physiological response data. PERLARA PBC: ACCELERATE THE DISCOVERY OF CURES ACROSS DISEASES Perlara was originally founded as Perlstein Lab, PBC in February 2014. Perlara is the first biotech Public Benefit Corporation (bioPBC) based in the Bay Area that is on a mission to accelerate the discovery of cures for rare genetic diseases and uncover underlying mechanisms that enable the development of treatments that work across a range of diseases and individuals. PERLARA PERLQUESTS TO FIND TREATMENTS FOR THOUSANDS OF Perlara embarks on journeys of discovery called PerlQuests™ with families, patient organizations and researchers to develop treatments for rare diseases. There are about 7000 rare diseases affecting 350 million people worldwide, of which roughly half are inherited, i.e. relating to genes. Until now, the cost of discovering chemicalcompounds
PERLARA FAQS. LEARN MORE ABOUT PERLARA PBC AND PERLQUESTS. Perlara PBC was originally founded as Perlstein Lab, PBC in February 2014. Perlara, PBC is a biotech platform company and Public Benefit Corporation (bioPBC) based in the San Francisco Bay Area that is on a mission to discover personalized cures for diseases rare and common.. We are a demographically diverse team with expertise in genetics, pharmacology, cell biology, data science and automation. PERLARA BLOG ABOUT OUR SCIENCE, RARE DISEASE COMMUNITY AND A blog about our science, the rare disease community and PerlQuests. Perlara Events - January 2019 Conducting a GNAO1 yeast screen Modeling Pompe disease in flies Last month in tweets - November 2018 Perlara Events - December 2018. Business. Perlara Events – January 2019.Perlara
PERLARK™ DRUG DISCOVERY PLATFORM USED TO IDENTIFY ORPHAN Perlara uses a platform of genetically engineered animals (yeast, nematodes, fruit flies and zebrafish) in phenotypic screens to identify orphan drug candidates that reverse disease much faster and cheaper than current approaches. PERLARA CAREERS IN SMALL MOLECULE THERAPEUTICS FOR ORPHAN Modeling CFTR-associated Pancreatitis in Budding Yeast. Perlara and Mission: Cure - a nonprofit organization with a mission to find a cure for those affected by pancreatitis - recently launched a Pancreatitis PerlQuest partnership. Ethan covers the backstory of this partnership - from the initial intro to developing a NIEMANN-PICK TYPE A PERLQUEST WITH WYLDER NATION Niemann-Pick Type A (NPA) affects about 1 in 250,000 individuals, with a higher frequency in individuals of Ashkenazi Jewish descent, where it's about 1 in 40,000. NPA is caused by a mutation in the SMPD1 gene, a gene encoding acid sphingomyelinase which, when In December of 2016, Perlara partnered with Wylder Nation to initiate an NPA POMPE DISEASE FLY MODEL Here at Perlara we are excited to announce our probe into Pompe disease which, along with Cori disease, comprise our glycogen storage disease PerlQuest.For this project we will be collaborating with the Warren Center at the University of Notre Dame.Our goal is to develop an accurate Pompe disease fly model, and to test a select group of candidate drugs in hopes of finding a promising treatment PERLARA PBC IS WORKING WITH FAMILIES TO DEVELOP CURES FORABOUT USOUR SCIENCEPERLQUESTSFAQSBLOGNEWS Perlara scientists are working with highly motivated families, patient organizations and researchers to develop cures for rare diseases and learn how genes work across diseases to map connections to common ailments. We call these exciting journeys of discoveryCONTACT - PERLARA
We’re having an ongoing conversation with families and researchers about collaborations that will lead to cures. Please contact us so that we can share what we learn, and learn from you. Email: info@perla ra.com. Office: 6000 Shoreline Ct. Suite 204. South San Francisco.California 94080.
PERLARA IS A PUBLIC BENEFIT CORPORATION ACCOUNTABLE FOR Public Benefit Corporation. We chose to incorporate as the first biotech Public Benefit Corporation because we are accountable for our actions as a company and as individuals within the context of a balanced and healthy global economy and environment. PBC report. Since our founding in 2014, our mission has guided our actions—fromoperating
PERLARK™ DRUG DISCOVERY PLATFORM USED TO IDENTIFY ORPHAN Perlara uses a platform of genetically engineered animals (yeast, nematodes, fruit flies and zebrafish) in phenotypic screens to identify orphan drug candidates that reverse disease much faster and cheaper than current approaches. PERLARA ANNOUNCES APOL1 KIDNEY DISEASE PERLQUEST Perlara, the rare diseases platform company that partners with highly motivated families, organizations, researchers and impact investors to cure rare genetic diseases, today announced an APOL1 kidney disease PerlQuest co-development partnership with Rambam Medical Center in Haifa, Israel, and the laboratory of leading nephrologist and kidney CONSERVATION OF FAT STORAGE AND MOBILIZATION IN Conservation of Fat Storage and Mobilization in Drosophila. Lipids are stored in cellular locales called “lipid droplets.”. The lipid droplet surface is a lipid monolayer coated with specific proteins. The best known lipid droplet surface proteins are “PAT” NEIMAN-PICK TYPE C KO MOUSE BRAIN STUDY The presence of CD68 is often used to measure the inflammatory response in the brain and is expressed more highly in many neurodegenerative diseases, including in the brains of Niemann Pick C mice and humans (brown areas of stain in panel (C) and (D) are of CD68). Figure 2. CD68 in the brain of NPC1 patient samples. ETHAN PERLSTEIN IS CHIEF EXECUTIVE OFFICER AT PERLARA. Ethan Perlstein, PhD | CEO. Over the course of the last decade, first as a graduate student at Harvard University in the Department of Molecular and Cell Biology with PhD advisor Professor Stuart Schreiber and then as an independent postdoctoral fellow at the Lewis-Sigler Institute at Princeton University, Dr. Ethan Perlstein developed an approach to studying old drugs and discovering new THE NIEMANN-PICK C/EBOLA CONNECTION Now, based on our previous NPC posts you know that individuals with Niemann-Pick type C disease accumulate cholesterol in the endosome/lysosome compartments. Researchers in this study checked to see if it was the accumulation of cholesterol that affected the lack of viral infectivity. They treated NPC2-/-, NPC2 +/- and wt littermates with EBOV. ACOUSTIC LIQUID HANDLING LABCYTE ECHO 550 FOR HIGH Labcyte Echo 550 acoustic liquid handling for high throughput screening of potential drug candidates. Liquid handling is essential to HTS assays as the drug discovery experiment pipeline includes screening millions of compounds to identify as a potential drug candidate. The A coustic Droplet Ejection (ADE) is a technology whichuses highly
PERLARA PBC IS WORKING WITH FAMILIES TO DEVELOP CURES FORABOUT USOUR SCIENCEPERLQUESTSFAQSBLOGNEWS Perlara scientists are working with highly motivated families, patient organizations and researchers to develop cures for rare diseases and learn how genes work across diseases to map connections to common ailments. We call these exciting journeys of discoveryCONTACT - PERLARA
We’re having an ongoing conversation with families and researchers about collaborations that will lead to cures. Please contact us so that we can share what we learn, and learn from you. Email: info@perla ra.com. Office: 6000 Shoreline Ct. Suite 204. South San Francisco.California 94080.
PERLARA IS A PUBLIC BENEFIT CORPORATION ACCOUNTABLE FOR Public Benefit Corporation. We chose to incorporate as the first biotech Public Benefit Corporation because we are accountable for our actions as a company and as individuals within the context of a balanced and healthy global economy and environment. PBC report. Since our founding in 2014, our mission has guided our actions—fromoperating
PERLARK™ DRUG DISCOVERY PLATFORM USED TO IDENTIFY ORPHAN Perlara uses a platform of genetically engineered animals (yeast, nematodes, fruit flies and zebrafish) in phenotypic screens to identify orphan drug candidates that reverse disease much faster and cheaper than current approaches. PERLARA ANNOUNCES APOL1 KIDNEY DISEASE PERLQUEST Perlara, the rare diseases platform company that partners with highly motivated families, organizations, researchers and impact investors to cure rare genetic diseases, today announced an APOL1 kidney disease PerlQuest co-development partnership with Rambam Medical Center in Haifa, Israel, and the laboratory of leading nephrologist and kidney CONSERVATION OF FAT STORAGE AND MOBILIZATION IN Conservation of Fat Storage and Mobilization in Drosophila. Lipids are stored in cellular locales called “lipid droplets.”. The lipid droplet surface is a lipid monolayer coated with specific proteins. The best known lipid droplet surface proteins are “PAT” NEIMAN-PICK TYPE C KO MOUSE BRAIN STUDY The presence of CD68 is often used to measure the inflammatory response in the brain and is expressed more highly in many neurodegenerative diseases, including in the brains of Niemann Pick C mice and humans (brown areas of stain in panel (C) and (D) are of CD68). Figure 2. CD68 in the brain of NPC1 patient samples. ETHAN PERLSTEIN IS CHIEF EXECUTIVE OFFICER AT PERLARA. Ethan Perlstein, PhD | CEO. Over the course of the last decade, first as a graduate student at Harvard University in the Department of Molecular and Cell Biology with PhD advisor Professor Stuart Schreiber and then as an independent postdoctoral fellow at the Lewis-Sigler Institute at Princeton University, Dr. Ethan Perlstein developed an approach to studying old drugs and discovering new THE NIEMANN-PICK C/EBOLA CONNECTION Now, based on our previous NPC posts you know that individuals with Niemann-Pick type C disease accumulate cholesterol in the endosome/lysosome compartments. Researchers in this study checked to see if it was the accumulation of cholesterol that affected the lack of viral infectivity. They treated NPC2-/-, NPC2 +/- and wt littermates with EBOV. ACOUSTIC LIQUID HANDLING LABCYTE ECHO 550 FOR HIGH Labcyte Echo 550 acoustic liquid handling for high throughput screening of potential drug candidates. Liquid handling is essential to HTS assays as the drug discovery experiment pipeline includes screening millions of compounds to identify as a potential drug candidate. The A coustic Droplet Ejection (ADE) is a technology whichuses highly
GET THE LATEST PERLARA NEWS ABOUT PERLQUESTS, SCIENCE, AND August 15, 2018. Perlara announces Glycogen Storage Diseases PerlQuest with the University of Notre Dame. July 11, 2018. Perlara announces n=1 drug discovery pact with Mission: Cure. April 9, 2018. Perlara announces partnership with Multiple Sulfatase Deficiency Action Foundation. March 2, 2018. Perlara announces collaboration withUndiagnosed
PERLARK DRUG DISCOVERY PLATFORM TO HELP FIND RARE DISEASE 1. Build an Ark. We use gene editing technology to model specific human diseases in simple animals like yeasts, worms, flies and fish. Think Noah’s Ark of Drug Discovery. 2. Try out a boat load of compounds. We screen compounds on our disease models, and gather massive amounts of chemical and physiological response data. PERLARA PBC: ACCELERATE THE DISCOVERY OF CURES ACROSS DISEASES Perlara was originally founded as Perlstein Lab, PBC in February 2014. Perlara is the first biotech Public Benefit Corporation (bioPBC) based in the Bay Area that is on a mission to accelerate the discovery of cures for rare genetic diseases and uncover underlying mechanisms that enable the development of treatments that work across a range of diseases and individuals. PERLARA PERLQUESTS TO FIND TREATMENTS FOR THOUSANDS OF Perlara embarks on journeys of discovery called PerlQuests™ with families, patient organizations and researchers to develop treatments for rare diseases. There are about 7000 rare diseases affecting 350 million people worldwide, of which roughly half are inherited, i.e. relating to genes. Until now, the cost of discovering chemicalcompounds
PERLARA FAQS. LEARN MORE ABOUT PERLARA PBC AND PERLQUESTS. Perlara PBC was originally founded as Perlstein Lab, PBC in February 2014. Perlara, PBC is a biotech platform company and Public Benefit Corporation (bioPBC) based in the San Francisco Bay Area that is on a mission to discover personalized cures for diseases rare and common.. We are a demographically diverse team with expertise in genetics, pharmacology, cell biology, data science and automation. PERLARA BLOG ABOUT OUR SCIENCE, RARE DISEASE COMMUNITY AND A blog about our science, the rare disease community and PerlQuests. Perlara Events - January 2019 Conducting a GNAO1 yeast screen Modeling Pompe disease in flies Last month in tweets - November 2018 Perlara Events - December 2018. Business. Perlara Events – January 2019.Perlara
PERLARK™ DRUG DISCOVERY PLATFORM USED TO IDENTIFY ORPHAN Perlara uses a platform of genetically engineered animals (yeast, nematodes, fruit flies and zebrafish) in phenotypic screens to identify orphan drug candidates that reverse disease much faster and cheaper than current approaches. PERLARA CAREERS IN SMALL MOLECULE THERAPEUTICS FOR ORPHAN Modeling CFTR-associated Pancreatitis in Budding Yeast. Perlara and Mission: Cure - a nonprofit organization with a mission to find a cure for those affected by pancreatitis - recently launched a Pancreatitis PerlQuest partnership. Ethan covers the backstory of this partnership - from the initial intro to developing a NIEMANN-PICK TYPE A PERLQUEST WITH WYLDER NATION Niemann-Pick Type A (NPA) affects about 1 in 250,000 individuals, with a higher frequency in individuals of Ashkenazi Jewish descent, where it's about 1 in 40,000. NPA is caused by a mutation in the SMPD1 gene, a gene encoding acid sphingomyelinase which, when In December of 2016, Perlara partnered with Wylder Nation to initiate an NPA POMPE DISEASE FLY MODEL Here at Perlara we are excited to announce our probe into Pompe disease which, along with Cori disease, comprise our glycogen storage disease PerlQuest.For this project we will be collaborating with the Warren Center at the University of Notre Dame.Our goal is to develop an accurate Pompe disease fly model, and to test a select group of candidate drugs in hopes of finding a promising treatment* Home
* About Us
* Public Benefit Corporation* Our Science
* Organic Intelligence * Deeper Perlara Science* PerlQuests
* Launching your PerlQuest* NGLY1
* NPA
* PMM2-CDG
* MSD
* GNAO1
* RPS6KA3
* Pancreatitis
* GSD III
* MPSIIIA
* MPSIIIB
* Leigh Syndrome
* APOL1 Kidney Disease* FAQs
* Blog
* News
* Contact
* Careers
Select Page
* Home
* About Us
* Public Benefit Corporation* Our Science
* Organic Intelligence * Deeper Perlara Science* PerlQuests
* Launching your PerlQuest* NGLY1
* NPA
* PMM2-CDG
* MSD
* GNAO1
* RPS6KA3
* Pancreatitis
* GSD III
* MPSIIIA
* MPSIIIB
* Leigh Syndrome
* APOL1 Kidney Disease* FAQs
* Blog
* News
* Contact
* Careers
*
NGLY1
PerlQuest
We identified tool compounds, repurposable drugs as well as novel chemotypes that rescue worm and fly disease models. Follow NGLY1 PerlQuest __*
Niemann-Pick
Type A
PerlQuest
We identified overlapping hits between worm and patient fibroblast drug repurposing screens. Follow NPA PerlQuest __*
PMM2- CDG
PerlQuest
We identified natural products and repurposable drugs that rescue yeast and worm disease models. Follow PMM2-CDG PerlQuest __*
Multiple
Sulfatase
Deficiency
PerlQuest
MSD mutant flies are in the lab and phenotyping has begun! Follow MSD PerlQuest __*
GNAO1
PerlQuest
"Perlara’s work will help put children with a GNAO1-related neurodevelopmental disorder further on the radar of researchers and pharmaceutical companies.” Follow GNAO1 PerlQuest __*
Coffin-Lowry
Syndrome
PerlQuest
"The collaborative drug discovery effort gives hope for new insights about CLS and better lives for our children.” Follow CLS PerlQuest __*
Pancreatitis
PerlQuest
We’re excited to break new ground scientifically with a yeast-to-organoid drug screening pipeline for pancreatitis and cystic fibrosis. Follow Pancreatitis PerlQuest __*
Cori Disease
PerlQuest
Perlara’s expertise will accelerate the identification of small molecules as potential treatments for GSD patients. Follow GSD III PerlQuest __*
MPSIIIA
PerlQuest
With children losing ground to this disease every day we have to we are hopeful that our PerlQuests will bring us ever closer to help for patients with Sanfilippo syndrome. Follow MPSIIIA PerlQuest __*
MPSIIIB
PerlQuest
We are developing nematode and fly disease models and screening compounds for promising leads. Stay tuned. Follow MPSIIIB PerlQuest __*
Leigh
Syndrome
PerlQuest
"A new treatment for Leigh syndrome could have broader implications for aging, sports medicine, traumatic brain injury, neurodegeneration and other indications." Follow Leigh Syndrome PerlQuest __*
APOL1
kidney disease
PerlQuest
"Genetic risk for APOL1 kidney disease affects ~100 millionpeople worldwide"
Follow APOL1 kidney disease PerlQuest __NGLY1
Niemann-Pick Type A
PMM2-CDG
Multiple Sulfatase DeficiencyGNAOI
Coffin-Lowry SyndromePancreatitis
Cori Disease
MPSIIIA
MSIIIB
Leigh Syndrome
APOL1 kidney disease PERLARA SCIENTISTS ARE WORKING WITH HIGHLY MOTIVATED FAMILIES, PATIENT ORGANIZATIONS AND RESEARCHERS TO DEVELOP CURES FOR RARE DISEASES AND LEARN HOW GENES WORK _ACROSS_ _DISEASES_ TO MAP CONNECTIONS TO COMMON AILMENTS. WE CALL THESE EXCITING JOURNEYS OF DISCOVERY PERLQUESTS™ Launch your own PerlQuest How does our science work? ORGANIC INTELLIGENCE (OI): MORE CURES FOR MORE INDIVIDUALS ANDDISEASES
Learn more about OI
PERLARA IN THE NEWS
-------------------------‹
›
Latest Press Release PERLARA ANNOUNCES APOL1 KIDNEY DISEASE PERLQUEST PARTNERSHIP WITH RAMBAM MEDICAL CENTERGNAO1
CONDUCTING A GNAO1 YEAST SCREEN As discussed in a previous post, we are currently working on a GNAO1 PerlQuest collaboration with the Undiagnosed Diseases Network...Gabriela Colmenares
GSD II
MODELING POMPE DISEASE IN FLIES Here at Perlara we are excited to announce our probe into Pompe disease which, along with Cori disease, comprise our glycogenstorage...
Madeleine Prangley
Home
About Us
Public Benefit CorporationOur Science
Perlquests
FAQs
Blog
News
Contact Us
Careers
Follow Us
* Follow
* Follow
* Follow
Join our mailing list Send__ Leave this field empty if you're human: 2019 Perlara, PBC | Privacy Policy | Terms of Use | Designed by Valley Design Group, Inc.__
__
__
__
Translate »
*
*
*
*
*
*
*
*
*
*
Select LanguageArabicChinese (Simplified)FrenchGermanHebrewItalianJapaneseRussianSpanishPowered byTranslate
ORIGINAL TEXT
Contribute a better translation -------------------------Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0